Italia markets closed

Faron Pharmaceuticals Oy (4FR.BE)

Berlin - Berlin Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
1,5900+0,0760 (+5,02%)
Alla chiusura: 09:33PM CEST
Schermo intero
Chiusura precedente1,5140
Aperto1,5140
Denaro1,4780 x 0
Lettera1,7020 x 0
Min-Max giorno1,5140 - 1,5940
Intervallo di 52 settimane1,3620 - 4,5500
Volume500
Media Volume7
CapitalizzazioneN/D
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patients

    Bexmarilimab produces a 50% remission rate in doublet dose cohorts (11 out of 22 patients)Eight of the 11 patients are Complete Responders (CR) or CR with incomplete blood recovery (CRi)Highest overall response rate (ORR) of 80% observed in prior HMA-failure MDS group (4 out of 5 patients)Bexmarilimab continues to be well-tolerated with no dose-limiting toxicity observedCompany to host virtual investor call to discuss data, today at 8:00 am EST Company announcement, Inside Information TURKU, Fin

  • GlobeNewswire

    Faron to Host Webcast to Discuss New Data From Phase I/II BEXMAB Study of Bexmarilimab and Provide Update on the Development Outlook for Next 6-9 Months

    TURKU, Finland and BOSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pioneering macrophage re-programming for effective cancer immunotherapies, today announces it will host a virtual call for investors to provide an update on the most recent Phase I/II BEXMAB data in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) on Wednesday, October 11 at 08.00 EST/13.00 BST/15.00 EEST. The new data co

  • GlobeNewswire

    Faron Pharmaceuticals Announces Board Changes

    TURKU, Finland and BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, is pleased to announce the appointment of Ms. Christine Roth and Dr. Marie-Louise Fjällskog as Non-Executive Directors of the Company with immediate effect following the passing of all resolutions put to shareholders of the Company at the Extraordinary General Meeting held earlie